In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Copley Pharmaceutical Inc.

Division of Teva Pharmaceutical Industries Ltd.

Latest From Copley Pharmaceutical Inc.

Teva's Growth Momentum

Teva has built a successful generics business by being nimble, aggressive and opportunistic, and is betting heavily that by dominating global markets it can prosper even after the end of the current spate of patent expirations. The success of its innovative drug Copaxone has given it a hedge against the volatility of generics and also changed the company in many ways. While Teva has to balance two very different businesses with limited synergies, it also must come up with a viable successor to Copaxone in order to secure its foothold in proprietary pharmaceuticals while continuing its investment in generics.
BioPharmaceutical Strategy

Teva's Growth Trend

Teva's strategy of becoming a leading global supplier of generics by acquiring companies in the US and Europe is paying off--the company's revenues grew nearly 40% last year. Moreover, the company's first branded product, Copaxone for multiple sclerosis, is finally garnering strong growth after a slow start.
BioPharmaceutical Business Strategies

Say Good-bye to the Family Farm

Watson Pharmaceuticals Inc.'s purchase of Schein Pharmaceutical seems to confirm what generics industry experts have known for some time: the industry is consolidating at both the wholesaler and manufacturer levels. The purchase, for $674 million and the assumption of $240 million in debt, is the third time in the past year that a large generics maker has bought a rival. The deal puts Watson, now ranked number four in generics, in a race for first place with Teva Pharmaceutical Industries Inc., which has also been on a buying spree.
BioPharmaceutical Strategy

Teva Ends Hoechst's Generics Misery

Teva Pharmaceuticals is buying Copley Pharmaceutical, another demonstratiion of brand-name companies' disappointment in generics as a business. Hoechst paid more than $500 million for Copley, which it bought in the heyday of brand-name companies' infatuation with the strategy of getting into the generics business in order to ward off fierce generics competition when key branded drugs go off patent. But Copley ran into regulatory problems above and beyond a flawed strategy. Teva, on the other hand, becomes the biggest US maker of generic pharmaceuticals in terms of volume, although Mylan is still slightly ahead in terms of revenues. This comes at a time when size is a key ingredient for success in generics due to the commodity-like nature of the business and customer consolidation.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Daniel K Korpolinski, Pres. & CEO
    Robert Brooke, VP, Quality Affairs
  • Contact Info
  • Copley Pharmaceutical Inc.
    Phone: (781) 821-6111
    25 John Rd.
    Canton, MA 02021